BioSpace News Archive

First study of RP7214, a DHODH inhibitor, in Covid-19 patients with mild, symptomatic disease on the background of promising preclinical efficacy & Phase 1 healthy volunteer safety

GE Healthcare unveiled Revolution Ascendvi with Effortless Workflow, offering clinicians a collection of artificial intelligence technologies that automate and simplify time-consuming tasks to increase operational efficiency and free up time for clinicians to deliver more personalized care to more patients.

Today, the U.S. Food and Drug Administration authorized marketing of software to assist medical professionals who examine body tissues (pathologists) in the detection of areas that are suspicious for cancer as an adjunct (supplement) to the review of digitally-scanned slide images from prostate biopsies (tissue removed from the body).

Kala Pharmaceuticals, Inc., announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635.